Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
Research ArticleArticle

Blood Monocyte Heterogeneity and Markers of Endothelial Activation in Ankylosing Spondylitis

Andrzej Surdacki, Joanna Sulicka, Mariusz Korkosz, Tomasz Mikołajczyk, Dorota Telesińska-Jasiówka, Ewa Klimek, Izabella Kierzkowska, Tomasz Guzik and Tomasz K. Grodzicki
The Journal of Rheumatology March 2014, 41 (3) 481-489; DOI: https://doi.org/10.3899/jrheum.130803
Andrzej Surdacki
From the Second Department of Cardiology, the Department of Rheumatology and Balneology, the Division of Rheumatology, Department of Internal Medicine and Gerontology, and the Department of Internal and Agricultural Medicine, Jagiellonian University Medical College and University Hospital; and J. Dietl Hospital, Krakow, Poland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: surdacki.andreas@gmx.net
Joanna Sulicka
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mariusz Korkosz
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tomasz Mikołajczyk
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dorota Telesińska-Jasiówka
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ewa Klimek
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Izabella Kierzkowska
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tomasz Guzik
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tomasz K. Grodzicki
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters
PreviousNext
Loading

Abstract

Objective. Ankylosing spondylitis (AS) is associated with excessive cardiovascular (CV) morbidity. Interactions between activated endothelium and monocytes precede atherosclerotic plaques. Our aim was to quantify blood monocyte subsets in relation to endothelial activation and inflammatory activity in subjects with AS who were free of clinical atherosclerotic CV disease.

Methods. Markers of inflammation and endothelial activation were measured in 47 patients with AS receiving no disease-modifying antirheumatic drugs, and 22 healthy controls. Exclusion criteria included atherosclerotic CV disease and traditional risk factors. Flow cytometry was used to identify monocyte subsets: classical CD14++CD16−, intermediate CD14++CD16+, and nonclassical CD14+CD16++ monocytes and to evaluate their expression of CD11b and CD11c.

Results. Traditional risk factors were comparable among the groups, except for lower high-density lipoprotein cholesterol in AS (p = 0.007). Relative to controls, in subjects with AS counts of classical monocytes were higher (84.3 ± 5.4 vs 78.9 ± 5.3% of blood monocytes, p < 0.001) and nonclassical monocytes lower (2.9 ± 2.2 vs 5.5 ± 2.3%, p < 0.001). In AS we observed increased soluble intercellular adhesion molecule-1 [251 (224–293) vs 202 (187–230) ng/ml, p = 0.002], an endothelial ligand for monocytic β2-integrin CD11b/CD18. CD11b expression on all 3 monocyte subsets was elevated in 21 AS subjects with a Bath Ankylosing Spondylitis Disease Activity Index score ≥ 4 versus the remaining patients (p = 0.005–0.03). C-reactive protein, interleukin 6 (IL-6), and pentraxin-3 were increased in AS, in contrast to tumor necrosis factor-α and IL-18. IL-6 correlated with classical monocytes numbers in AS (r = 0.56, p < 0.0001) but not in the controls (r = 0.10, p = 0.65).

Conclusion. Our findings suggest a contribution of immune dysregulation to enhanced monocyte-endothelial interactions in AS, especially in patients with active disease, which possibly can accelerate atherogenesis on a longterm basis.

Key Indexing Terms:
  • ANKYLOSING SPONDYLITIS
  • MONOCYTES
  • ENDOTHELIUM

Rheumatoid arthritis (RA), ankylosing spondylitis (AS), and psoriatic arthritis are associated with increased cardiovascular (CV) mortality and morbidity because of accelerated atherogenesis and disease-specific CV manifestations1,2,3. Features of endothelial dysfunction, a predecessor of atherosclerotic plaques, have been observed in patients with each of these inflammatory arthropathies and free of clinical atherosclerotic CV disease or classical risk factors4,5,6,7,8,9.

Interactions between activated endothelium and blood monocytes precede development of atherosclerotic plaques10. It has been recognized that not only endothelial dysfunction10,11,12 but also a shift in blood monocyte subsets can predict adverse CV outcome in various clinical settings13,14,15,16. Elevated counts of intermediate CD14++CD16+ monocytes (a minor monocyte subpopulation presumably representing a transitory stage of differentiation of predominant classical CD14++CD16− monocytes toward nonclassical CD14+CD16++ macrophage-like monocytes17) were associated with increased risk of ischemic CV events in endstage renal disease13 and nondialysis chronic kidney disease (CKD)14, and excessive risk of major CV events in patients referred for coronary angiography16. An increased frequency of CD14/CD16–double-positive monocytes or intermediate CD14++CD16+ monocytes was also reported in RA18,19,20 and psoriatic arthritis21. We have recently described elevated counts of intermediate monocytes in young adult survivors of childhood acute lymphoblastic leukemia22, also known to exhibit endothelial dysfunction23 and to be prone to late CV morbidity24.

To our knowledge, no study has focused on blood monocyte heterogeneity in AS to date. Thus, our aim was to estimate frequencies of circulating monocyte subsets and their relations with markers of endothelial dysfunction and inflammatory activity in patients naive to disease-modifying antirheumatic drugs (DMARD) and having AS free of clinical atherosclerotic CV disease.

MATERIALS AND METHODS

Subjects

We studied 47 patients aged 20–47 years (mean ± SD, 33 ± 6 yrs; 41 men and 6 women) with AS diagnosed according to the modified New York criteria25. All patients had predominantly axial disease and were HLA-B27–positive. The patients were receiving only nonsteroidal antiinflammatory drugs and none of them had been treated with nonbiologic DMARD, anti-tumor necrosis factor (anti-TNF) agents, or steroids. The mean disease duration was 8 ± 5 years. Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) scores26 averaged 4.1 ± 2.0 (range: 1.4–9.5). We also recruited a control group of 22 healthy volunteers aged 22–42 years (mean 30 ± 7 yrs; 12 men and 10 women).

Exclusion criteria were common for both groups and included clinical evidence of atherosclerotic CV disease, diabetes, hypertension, an estimated glomerular filtration rate (eGFR) below 90 ml/min per 1.73 m2 of body surface area, a history of malignancy, acute infections within previous 4 weeks, and any other chronic coexistent diseases. In agreement with the Declaration of Helsinki, the protocol had been approved by the ethics committee of our university, and written informed consent was obtained from each subject before inclusion in the study.

Study protocol

The procedure was carried out in the morning in the out-patient clinic of our center. The subjects had been asked to refrain from eating, smoking, and alcohol or caffeine consumption for at least 12 h prior to the study. The personnel involved in the protocol recorded demographic and clinical characteristics, anthropometric measurements were taken, and blood pressure was measured on the left arm after 5 min of rest in a sitting position. Then all participants underwent blood sampling for biochemical assays and flow cytometry.

Biochemical assays

A sample of blood was drawn from a left antecubital vein for measurements of serum concentrations of high-sensitivity C-reactive protein (hs-CRP) by immunonephelometry (Dade Behring II Nephelometer, GMI Inc.). Glucose, lipids, and creatinine were measured with a Hitachi 917 analyzer (Roche Diagnostics) using standardized laboratory techniques. An eGFR was calculated by the Chronic Kidney Disease Epidemiology Collaboration formula, which has proven more accurate than the Modification of Diet in Renal Disease study equation, especially at normal renal function27.

Plasma for extended biochemical analyses was collected from EDTA-anticoagulated blood and frozen at −80°C until assayed. Commercially available ELISA were used to measure plasma levels of TNF-α and interleukin 6 (IL)-6 (Quantikine high-sensitivity kits), monocyte chemotactic protein-1 (MCP-1), pentraxin-3 (PTX-3), soluble forms of vascular cell adhesion molecule-1 (sVCAM-1) and intercellular adhesion molecule-1 (sICAM-1; all R&D Systems), and IL-18 (MBL).

Flow cytometry

As described22, peripheral blood mononuclear cells were isolated from EDTA-anticoagulated blood and collected on the same day as remaining samples, using density gradient centrifugation and LSM 1077 (Lymphocyte Separation Medium, PAA Laboratories GmbH). One hundred thousand cells were stained for 20 min with fluorochrome-conjugated monoclonal antibodies (anti-CD14-APC-H7, anti-CD16-PE, anti-HLA-DR-PE-Cy7, anti-CD11b-Pacific Blue; and anti-CD11c-APC; Becton Dickinson Biosciences — Pharmingen) and then washed with phosphate buffered saline containing 1% fetal bovine serum (GIBCO). The cells were processed in the FACSCanto II flow cytometer (BD Biosciences) and then analyzed with FACSDiva software (BD Biosciences) and FlowJo (TreeStar Inc.). The cells were gated in a side scatter/forward scatter plot with the scatter gate for monocytes partially extending into lymphocytes28. The cells containing all monocytes and a part of the lymphocyte population were then gated in an HLA-DR/CD14 plot to exclude HLA-DR–negative natural killer cells (which would otherwise contaminate the CD14+CD16++ subpopulation) and finally analyzed for CD14 and CD16 expression28,29. Monocyte subsets were defined according to the expression of CD16 (Fcγ receptor type III) and CD14 (lipopolysaccharide receptor) as classical monocytes (CD14++CD16−), intermediate monocytes (CD14++CD16+), and nonclassical monocytes (CD14+CD16++)17. The expression of CD11b and CD11c on the 3 monocyte subsets was quantified. The results have been presented as either the percentage of cells expressing individual markers, absolute cell counts (per μl of blood), or mean fluorescence intensity (MFI). Total numbers of monocytes were calculated using peripheral white blood cell counts. In separate experiments BD Trucount beads were used, confirming that both methods yielded similar absolute values of cell counts.

All experiments were performed under standardized experimental conditions, including the procedure of cell isolation and reagents for sample preparation. The same number of cells and the same amounts of antibodies were used for samples. Simultaneously, in each case we checked the proper operation of the flow cytometer using BD Cytometer Setup and Tracking beads. Also, the operational stability was verified, so that the individual measurements did not differ significantly one from the other. Flow cytometry compensation was verified regularly using cells studied in the experiment and CompBeads. One operator performed the sample collection and the data analysis.

Statistical analysis

Data are presented as mean ± SD unless stated otherwise or medians (interquartile range) for continuous variables, and numbers (percentages) for categorical variables. The accordance with a normal distribution was tested by the Kolmogorov-Smirnov test, and uniformity of variance (homoscedasticity) by Levene’s test. Intergroup differences were assessed by the unpaired 2-sided Student’s t test for continuous variables and Fisher’s exact test for proportions. Logarithmic transformation (ln, natural logarithm) was applied, when necessary, to obtain a normal distribution (hs-CRP, TNF-α, IL-6, sVCAM-1, PTX-3, percentage of intermediate monocytes) or to eliminate the nonuniformity of variances. The 2-sided Welch’s t test was used in case of the lack of homogeneity of variances even in ln-transformed data. A p-value below 0.05 was considered significant. Bivariate relations between continuous variables were estimated by Pearson’s correlation coefficients (r). Owing to multiple testing, exclusive correlations with p ≤ 0.001 were inferred as significant. Analyses were performed by means of the Statistica data analysis software system (version 10.0.1011.0; StatSoft Inc.).

RESULTS

Clinical and biochemical characteristics of the patients with AS and healthy controls

Traditional CV risk factors were similar in patients with AS and healthy controls except for lower high-density lipoprotein (HDL) cholesterol, in agreement with a previous report30, and a higher ratio of total cholesterol to HDL cholesterol in AS (Table 1). Additionally, levels of fibrinogen, hs-CRP, IL-6, sICAM-1, and PTX-3 were significantly increased in patients with AS, whereas TNF-α, sVCAM-1, IL-18, and MCP-1 were similar between the groups (Table 2).

View this table:
  • View inline
  • View popup
Table 1.

Clinical and conventional biochemical characteristics of patients with ankylosing spondylitis (AS) and control subjects. Data are shown as medians (interquartile range) or n (%). P values in boldface are statistically significant.

View this table:
  • View inline
  • View popup
Table 2.

Extended inflammatory markers in ankylosing spondylitis (AS) patients and controls. Data are shown as medians (interquartile range). P values in boldface are statistically significant.

Blood monocyte subsets and their expression of CD11b and CD11c in patients with AS and healthy controls

Compared to the controls, patients with AS exhibited significantly higher counts of classical CD14++CD16− monocytes and lower numbers of nonclassical CD14+CD16++ monocytes (Table 3). There were no differences in the expression of CD11b and CD11c on all 3 monocyte subsets between AS subjects and the controls (p > 0.1).

View this table:
  • View inline
  • View popup
Table 3.

Monocyte subsets and total monocyte counts in ankylosing spondylitis (AS) patients and healthy subjects. Data are shown as mean ± SD. P values in boldface are statistically significant.

Pooling both groups as a whole, men tended to have higher total monocyte counts than women (536 ± 208 vs 436 ± 115 cells/μl, p = 0.09). Because the percentage of men was higher in patients with AS (87% vs 55%), we repeated the comparisons after limitation of the analysis to male subjects, which revealed similar directions and levels of significance for intergroup differences in classical (p = 0.001) and nonclassical (p < 0.001) monocytes.

There was a correlation between IL-6 and the count of classical monocytes in patients with AS (r = 0.56, p < 0.0001; (Table 4 and Figure 1A) but not in the controls (r = 0.10, p = 0.65; Figure 1B). Neither HDL cholesterol nor the ratio of total to HDL cholesterol correlated to any of the variables derived from flow cytometry (p ≥ 0.1).

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

A positive correlation between the numbers of classical monocytes and interleukin 6 levels in patients with ankylosing spondylitis (A) but not in the controls (B). Levels of interleukin 6 were transformed in natural logarithm (Ln) to obtain a normal distribution.

View this table:
  • View inline
  • View popup
Table 4.

Pearson’s correlation coefficients between inflammatory markers, disease activity, monocyte subsets size, and monocytic CD11b and CD11c expression in patients with ankylosing spondylitis. Data in boldface are statistically significant.

Clinical and biochemical characteristics, monocyte subset size, and monocytic expression of CD11b and CD11c in relation to disease activity

BASDAI correlated to the expression of CD11b on classical (r = 0.47, p = 0.001), intermediate (r = 0.49, p < 0.001), and nonclassical monocytes (r = 0.52, p < 0.001; Table 4). Accordingly, compared to AS patients with a BASDAI score < 4 (n = 26), AS patients with BASDAI ≥ 4 (n = 21) had higher monocytic expression of CD11b on classical (1529 ± 1006 vs 998 ± 591 MFI, p = 0.03; Figure 2A), intermediate (1591 ± 899 vs 1009 ± 579 MFI, p = 0.01; Figure 2B), and nonclassical monocytes (607 ± 185 vs 461 ± 143 MFI, p = 0.005; Figure 2C). Relative increases in CD11b expression on classical, intermediate, and nonclassical monocytes associated with a high disease activity averaged 53%, 58%, and 32%, respectively, with the reference to the remaining subjects with AS. The expression of CD11b was reduced by about one-third in the patients with AS who had a low disease activity, relative to controls on all 3 monocyte subpopulations: classical (998 ± 591 vs 1539 ± 629 MFI, p = 0.003), intermediate (1009 ± 579 vs 1523 ± 584 MFI, p = 0.004), and nonclassical monocytes (461 ± 143 vs 729 ± 566 MFI, p = 0.02).

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Elevated CD11b expression on classical (A), intermediate (B), and nonclassical (C) monocytes in subjects with ankylosing spondylitis and a BASDAI score ≥ 4 (n = 21) compared to the remaining patients (n = 26). Data are shown as means ± SE of the mean; p values by Student’s t test. BASDAI: Bath Ankylosing Spondylitis Disease Activity Index score; MFI: mean fluorescence intensity.

The AS patients with a BASDAI score ≥ 4 and < 4 did not differ in terms of traditional risk factors (p > 0.1), levels of sICAM-1 (270 ± 70 vs 262 ± 50 ng/ml, p = 0.7, respectively), sVCAM-1 [541 (491–607) vs 591 (500–658) ng/ml, p = 0.08], hs-CRP [7.02 (2.57–18.20) vs 5.05 (2.95–13.60) mg/l, p = 0.8], PTX-3 [631 (421–739) vs 551 (483–772) pg/ml, p = 0.6], TNF-α [1.77 (1.50–2.20) vs 1.80 (1.58–2.07) pg/ml, p = 0.8], IL-6 [3.09 (2.24–6.98) vs 3.55 (1.80–5.55) pg/ml, p = 0.5], IL-18 [446 ± 137 vs 422 ± 153 pg/ml, p = 0.6], MCP-1 [252 ± 72 vs 264 ± 74 pg/ml, p = 0.6], and size of monocyte subsets (p = 0.4–0.8; Table 4).

The expression of CD11c was similar in patients with AS who had high disease activity, low disease activity, and the controls on classical (1475 ± 638 vs 1522 ± 497 vs 1695 ± 1231 MFI, respectively), intermediate (3381 ± 1025 vs 3468 ± 1040 vs 3983 ± 2612 MFI), and nonclassical monocytes (3620 ± 972 vs 3809 ± 1029 vs 3635 ± 2359 MFI; all intergroup p = 0.3–0.9).

DISCUSSION

Our salient finding was a higher number of classical CD14++CD16− blood monocytes and its association with elevated IL-6 levels in DMARD-naive patients with AS. This study is the first, to our knowledge, to report a shift in blood monocyte subpopulations in AS. Additionally, in AS we observed increased sICAM-1, a marker of endothelial activation and an endothelial ligand for monocytic β2-integrin CD11b/CD18. Moreover, on all 3 monocyte subsets the expression of CD11b was decreased in AS subjects with low disease activity compared to those with high disease activity, or healthy controls.

The shift in monocyte subsets in AS differed from the previously observed expansion of CD14/CD16–double positive monocytes18,20 or CD14++CD16+ intermediate monocytes19 in RA. This might result from distinct pathogenesis of these 2 forms of inflammatory arthritis. However, we have not studied patients with RA, which limits comparisons of our findings with those reports18,19,20.

That the observed increase in CD14++CD16− monocyte counts in AS correlated to 6-fold elevated IL-6 levels, but not TNF-α or IL-18 concentrations, is compatible with a high secretion of IL-6 by classical monocytes from healthy individuals in response to lipopolysaccharide31,32. Because IL-6 (besides inducing the synthesis of acute-phase reactants) plays a role in the differentiation of Th1733 and Th2 cells34, this relationship may reflect the contribution of a shift in blood monocyte subpopulations to the pathogenesis of AS, reportedly associated with a 10-fold increase in the percentage of Th17 cells among peripheral blood mononuclear cells without in vitro stimulation35. Nevertheless, it is unknown whether classical monocytes have the same properties in patients with AS and healthy subjects.

Previous reports relating monocyte heterogeneity to CV prognosis are inconsistent. A higher frequency of intermediate monocytes but not classical monocytes independently predicted adverse CV outcome in 94 patients receiving dialysis and in 119 nondialysis CKD subjects followed for about 3 and 5 years, respectively13,14. In 951 patients referred for elective coronary angiography, mainly with prevalent coronary artery disease (CAD) or cerebrovascular disease, both classical and intermediate monocytes emerged as univariate predictors of major CV events during a mean followup of 2.6 years, whereas upon multivariate adjustment the statistical significance was retained exclusively for intermediate monocytes16. Therefore, our findings might suggest that excessive CV risk in AS might be independent of a shift in favor of classical monocytes.

On the other hand, classical monocytes, but not other monocyte subsets, independently predicted ischemic CV events in 700 randomly selected participants of the cardiovascular arm of the Malmö Diet and Cancer study over a 15-year followup15. Additionally, in a group of high-risk patients with stable CAD36, the proportion of classical monocytes was elevated at the expense of nonclassical monocytes, as in our AS subjects, compared to low-risk and medium-risk groups delineated on the basis of the number of traditional risk factors in 80 subjects with CAD. Further, Urra, et al37 found a positive association between classical monocytes (which exhibited the highest platelet-monocyte interactions) and 3-month mortality in 46 consecutive patients with stroke.

However, the published observations on the association between adverse CV outcome and classical CD14++CD16− monocytes or intermediate CD14++CD16+ monocytes may be not entirely contradictory because Cros, et al31 have provided evidence (by means of whole-genome expression arrays) that both classical and intermediate human monocytes resemble murine Ly6ChighGr+ monocytes, exhibiting preferential homing to activated endothelium and atherosclerotic plaques in experimental models of atherosclerosis38,39,40. In addition, preferential transendothelial migration in response to MCP-1 was demonstrated for human classical monocytes as compared to the other monocyte subsets41. Moreover, classical monocytes are the main source of reactive oxygen species31,42 known to impair the activity of nitric oxide43, an endogenous antiatherogenic molecule.

Thus, an increased frequency of classical monocytes in our subjects with AS who had elevated sICAM-1, an index of endothelial activation and an endothelial ligand for monocytic β2-integrin CD11b/CD1844, supported by a relative increase in the expression of CD11b on classical and intermediate monocytes by over 50% in patients with active disease compared to those with low disease activity, might reflect enhanced leukocyte-endothelial interactions and chronic inflammation within the vascular wall10. Because BASDAI score had been reportedly associated with traditional risk factors, including metabolic syndrome components45,46, the leukocyte-endothelial interactions could potentiate pro-atherogenic effects of the classical risk factors in patients with high disease activity. Admittedly, monocytic CD11b expression did not differ between the patients with AS who had active disease and the controls; nevertheless, a decreased CD11b expression on monocytes of the subjects with AS who had low disease activity could hypothetically reflect an effective compensatory antiinflammatory mechanism that was absent in those with a BASDAI score ≥ 4. This suggestion remains speculative and requires further investigation.

On the other hand, the biological significance of relatively small differences in sICAM-1 levels and the frequency of classical monocytes remains unclear. Nevertheless, compared to controls, patients with AS exhibited higher average relative elevations of these variables [classical monocytes: 469 vs 364 per μl of blood (29%); sICAM-1: 251 vs 202 ng/ml (25%)] than those previously reported in participants who later experienced an ischemic CV event versus the event-free subjects in prospective studies [classical monocytes: 344 vs 297 per μl of blood (16%) in the Malmö Diet and Cancer study15; sICAM-1: 289 vs 244 ng/ml (18%) in the Atherosclerosis Risk in Communities study47].

It is noteworthy that PTX-3, elevated in patients with AS, is released locally from cells involved in atherogenesis and (despite its atheroprotective effects) can be considered a marker of vascular inflammation48. Further, higher PTX-3 levels predicted CV mortality independently of hs-CRP and traditional risk factors in subjects free of prevalent CV disease49. However, we have provided no direct evidence supporting the notion of a better ability of PTX-3, adhesion molecules, or monocyte subsets to predict accelerated atherogenesis compared to classical risk factors and conventional inflammatory markers in AS. To verify this speculative concept, further studies are warranted, relating these variables to coexistent atherosclerotic CV disease or subclinical atherosclerosis in patients with AS.

Several limitations of our study need to be acknowledged. First, the small number of subjects constrains the conclusions based on our findings. Second, we have measured cytokines and chemokines in plasma, whereas the assessment of cytokine generation in response to various stimuli and the expression of chemokine receptors by different monocyte subsets would add information to the in situ plasma levels18,19,31,32,42. Third, we are not able to exclude the influence of nonsteroidal antiinflammatory drugs on the activation of both monocytes and endothelial cells in patients with AS. Fourth, blood monocyte subpopulations might be affected by lipids50, and a lower level of HDL cholesterol was observed in subjects with AS. However, no lipid variable correlated to the size of any of the monocyte subsets or their β2-integrin expression in our study. Finally, although we made every effort to ensure similar characteristics in both groups, the percentage of men was higher in AS. Rogacev, et al16 described higher absolute counts of classical monocytes in men referred for elective coronary angiography mainly because of increased numbers of total monocytes, also present in our data. Nevertheless, we observed intergroup differences in both relative and absolute counts of classical monocytes, which argues against the notion of sex differences in total monocyte counts as an explanation of our results. In addition, the results have not changed after limitation of the analysis to male subjects.

Patients with AS exhibit a shift in blood monocyte subpopulations. Our preliminary cross-sectional findings suggest contribution of immune dysregulation to enhanced monocyte-endothelial interactions in AS, especially in patients with active disease, which possibly can accelerate atherogenesis on a longterm basis. Further longitudinal studies are warranted to determine the relevance of these abnormalities for late CV morbidity.

Footnotes

  • Dr. Surdacki and Dr. Sulicka contributed equally to this work and are co-first authors.

  • Supported in part by a research grant from the Ministry of Science and Higher Education, Warsaw, Poland (No. N402 267636).

  • Accepted for publication November 27, 2013.

REFERENCES

  1. 1.↵
    1. Peters MJ,
    2. Symmons DP,
    3. McCarey D,
    4. Dijkmans BA,
    5. Nicola P,
    6. Kvien TK,
    7. et al.
    EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010;69:325–31.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Peters MJ,
    2. van der Horst-Bruinsma IE,
    3. Dijkmans BA,
    4. Nurmohamed MT
    . Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum 2004;34:585–9.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Szabo SM,
    2. Levy AR,
    3. Rao SR,
    4. Kirbach SE,
    5. Lacaille D,
    6. Cifaldi M,
    7. et al.
    Increased risk of cardiovascular and cerebrovascular diseases in individuals with ankylosing spondylitis: a population-based study. Arthritis Rheum 2011;63:3294–304.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Vaudo G,
    2. Marchesi S,
    3. Gerli R,
    4. Allegrucci R,
    5. Giordano A,
    6. Siepi D,
    7. et al.
    Endothelial dysfunction in young patients with rheumatoid arthritis and low disease activity. Ann Rheum Dis 2004;63:31–5.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Surdacki A,
    2. Martens-Lobenhoffer J,
    3. Wloch A,
    4. Marewicz E,
    5. Rakowski T,
    6. Wieczorek-Surdacka E,
    7. et al.
    Elevated plasma asymmetric dimethyl-L-arginine levels are linked to endothelial progenitor cell depletion and carotid atherosclerosis in rheumatoid arthritis. Arthritis Rheum 2007;56:809–19.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Surdacki A,
    2. Martens-Lobenhoffer J,
    3. Wloch A,
    4. Gluszko P,
    5. Rakowski T,
    6. Dubiel JS,
    7. et al.
    Plasma asymmetric dimethylarginine is related to anticitrullinated protein antibodies in rheumatoid arthritis of short duration. Metabolism 2009;58:316–8.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Aari I,
    2. Okan T,
    3. Akar S,
    4. Cece H,
    5. Altay C,
    6. Secil M,
    7. et al.
    Impaired endothelial function in patients with ankylosing spondylitis. Rheumatology 2006;45:283–6.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Gonzalez-Juanatey C,
    2. Llorca J,
    3. Amigo-Diaz E,
    4. Dierssen T,
    5. Martin J,
    6. Gonzalez-Gay MA
    . High prevalence of subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum 2007;57:1074–80.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Sari I,
    2. Kebapcilar L,
    3. Alacacioglu A,
    4. Bilgi O,
    5. Yildiz Y,
    6. Taylan A,
    7. et al.
    Increased levels of asymmetric dimethylarginine (ADMA) in patients with ankylosing spondylitis. Intern Med 2009;48:1363–8.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Hansson GK
    . Mechanisms of disease: inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352:1685–95.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Al Suwaidi J,
    2. Hamasaki S,
    3. Higano ST,
    4. Nishimura RA,
    5. Holmes DR Jr.,
    6. Lerman A
    . Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000;101:948–54.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Schächinger V,
    2. Britten MB,
    3. Zeiher AM
    . Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000;101:1899–906.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Heine GH,
    2. Ulrich C,
    3. Seibert E,
    4. Seiler S,
    5. Marell J,
    6. Reichart B,
    7. et al.
    CD14++CD16+ monocytes but not total monocyte numbers predict cardiovascular events in dialysis patients. Kidney Int 2008;73:622–9.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Rogacev KS,
    2. Seiler S,
    3. Zawada AM,
    4. Reichart B,
    5. Herath E,
    6. Roth D,
    7. et al.
    CD14++CD16+ monocytes and cardiovascular outcome in patients with chronic kidney disease. Eur Heart J 2011;32:84–92.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. Berg KE,
    2. Ljungcrantz I,
    3. Andersson L,
    4. Bryngelsson C,
    5. Hedblad B,
    6. Fredrikson GN,
    7. et al.
    Elevated CD14++CD16-monocytes predict cardiovascular events. Circulation Cardiovasc Genet 2012;5:122–31.
    OpenUrlCrossRef
  16. 16.↵
    1. Rogacev KS,
    2. Cremers B,
    3. Zawada AM,
    4. Seiler S,
    5. Binder N,
    6. Ege P,
    7. et al.
    CD14++CD16+ monocytes independently predict cardiovascular events: a cohort study of 951 patients referred for elective coronary angiography. J Am Coll Cardiol 2012;60:1512–20.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Ziegler-Heitbrock L,
    2. Ancuta P,
    3. Crowe S,
    4. Dalod M,
    5. Grau V,
    6. Hart DN,
    7. et al.
    Nomenclature of monocytes and dendritic cells in blood. Blood 2010;116:e74–80.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Kawanaka N,
    2. Yamamura M,
    3. Aita T,
    4. Morita Y,
    5. Okamoto A,
    6. Kawashima M,
    7. et al.
    CD14+,CD16+ blood monocytes and joint inflammation in rheumatoid arthritis. Arthritis Rheum 2002;46:2578–86.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Rossol M,
    2. Kraus S,
    3. Pierer M,
    4. Baerwald C,
    5. Wagner U
    . The CD14 brightCD16+ monocyte subset is expanded in rheumatoid arthritis and promotes expansion of the Th17-cell population. Arthritis Rheum 2012;64:671–7.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Cooper DL,
    2. Martin SG,
    3. Robinson JI,
    4. Mackie SL,
    5. Charles CJ,
    6. Nam J,
    7. et al.
    FcγRIIIa expression on monocytes in rheumatoid arthritis: role in immune-complex stimulated TNF production and non-response to methotrexate therapy. PLoS ONE 2012;7:e28918.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Chiu YG,
    2. Shao T,
    3. Feng C,
    4. Mensah KA,
    5. Thullen M,
    6. Schwarz EM,
    7. et al.
    CD16 (FcRγIII) as a potential marker of osteoclast precursors in psoriatic arthritis. Arthritis Res Ther 2010;12:R14.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Sulicka J,
    2. Surdacki A,
    3. Mikołajczyk T,
    4. Strach M,
    5. Gryglewska B,
    6. Ćwiklińska M,
    7. et al.
    Elevated markers of inflammation and endothelial activation and increased counts of intermediate monocytes in adult survivors of childhood acute lymphoblastic leukemia. Immunobiology 2013;218:810–6.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Dengel DR,
    2. Ness KK,
    3. Glasser SP,
    4. Williamson EB,
    5. Baker KS,
    6. Gurney JG
    . Endothelial function in young adult survivors of childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2008;30:20–5.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Mulrooney DA,
    2. Yeazel MW,
    3. Kawashima T,
    4. Mertens AC,
    5. Mitby P,
    6. Stovall M,
    7. et al.
    Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ 2009;339:b4606.
    OpenUrlAbstract/FREE Full Text
  25. 25.↵
    1. van der Linden S,
    2. Valkenburg HA,
    3. Cats A
    . Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361–8.
    OpenUrlCrossRefPubMed
  26. 26.↵
    1. Garrett S,
    2. Jenkinson T,
    3. Kennedy LG,
    4. Whitelock H,
    5. Gaisford P,
    6. Calin A
    . A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286–91.
    OpenUrlPubMed
  27. 27.↵
    1. Levey AS,
    2. Stevens LA,
    3. Schmid CH,
    4. Zhang YL,
    5. Castro AF 3rd.,
    6. Feldman HI,
    7. et al; and
    8. CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration)
    . A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604–12.
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Heimbeck I,
    2. Hofer TP,
    3. Eder C,
    4. Wright AK,
    5. Frankenberger M,
    6. Marei A,
    7. et al.
    Standardized single-platform assay for human monocyte subpopulations: lower CD14+CD16++ monocytes in females. Cytometry A 2010;77:823–30.
    OpenUrlPubMed
  29. 29.↵
    1. Siedlar M,
    2. Strach M,
    3. Bukowska-Strakova K,
    4. Lenart M,
    5. Szaflarska A,
    6. Węglarczyk K,
    7. et al.
    Preparations of intravenous immunoglobulins diminish the number and proinflammatory response of CD14+CD16++ monocytes in common variable immunodeficiency (CVID) patients. Clin Immunol 2011;139:122–32.
    OpenUrlCrossRefPubMed
  30. 30.↵
    1. Divecha H,
    2. Sattar N,
    3. Rumley A,
    4. Cherry L,
    5. Lowe GD,
    6. Sturrock R
    . Cardiovascular risk parameters in men with ankylosing spondylitis in comparison with non-inflammatory control subjects: relevance of systemic inflammation. Clin Sci 2005;109:171–6.
    OpenUrlCrossRefPubMed
  31. 31.↵
    1. Cros J,
    2. Cagnard N,
    3. Woollard K,
    4. Patey N,
    5. Zhang SY,
    6. Senechal B,
    7. et al.
    Human CD14dim monocytes patrol and sense nucleic acids and viruses via TLR7 and TLR8 receptors. Immunity 2010;33:375–86.
    OpenUrlCrossRefPubMed
  32. 32.↵
    1. Ziegler-Heitbrock HW,
    2. Ströbel M,
    3. Kieper D,
    4. Fingerle G,
    5. Schlunck T,
    6. Petersmann I,
    7. et al.
    Differential expression of cytokines in human blood monocyte subpopulations. Blood 1992;79:503–11.
    OpenUrlAbstract/FREE Full Text
  33. 33.↵
    1. Samson M,
    2. Audia S,
    3. Janikashvili N,
    4. Ciudad M,
    5. Trad M,
    6. Fraszczak J,
    7. et al.
    Brief report: inhibition of interleukin-6 function corrects Th17/Treg cell imbalance in patients with rheumatoid arthritis. Arthritis Rheum 2012;64:2499–503.
    OpenUrlCrossRefPubMed
  34. 34.↵
    1. Rincón M,
    2. Anguita J,
    3. Nakamura T,
    4. Fikrig E,
    5. Flavell RA
    . Interleukin (IL)-6 directs the differentiation of IL-4-producing CD4+ T cells. J Exp Med 1997;185:461–9.
    OpenUrlAbstract/FREE Full Text
  35. 35.↵
    1. Limón-Camacho L,
    2. Vargas-Rojas MI,
    3. Vázquez-Mellado J,
    4. Casasola-Vargas J,
    5. Moctezuma JF,
    6. Burgos-Vargas R,
    7. et al.
    In vivo peripheral blood proinflammatory T cells in patients with ankylosing spondylitis. J Rheumatol 2012;39:830–5.
    OpenUrlAbstract/FREE Full Text
  36. 36.↵
    1. Hristov M,
    2. Leyendecker T,
    3. Schuhmann C,
    4. Von Hundelshausen P,
    5. Heussen N,
    6. Kehmeier E,
    7. et al.
    Circulating monocyte subsets and cardiovascular risk factors in coronary artery disease. Thromb Haemost 2010;104:412–4.
    OpenUrlCrossRefPubMed
  37. 37.↵
    1. Urra X,
    2. Villamor N,
    3. Amaro S,
    4. Gómez-Choco M,
    5. Obach V,
    6. Oleaga L,
    7. et al.
    Monocyte subtypes predict clinical course and prognosis in human stroke. J Cereb Blood Flow Metab 2009;29:994–1002.
    OpenUrlCrossRefPubMed
  38. 38.↵
    1. Swirski FK,
    2. Weissleder R,
    3. Pittet MJ
    . Heterogeneous in vivo behavior of monocyte subsets in atherosclerosis. Arterioscler Thromb Vasc Biol 2009;29:1424–32.
    OpenUrlAbstract/FREE Full Text
  39. 39.↵
    1. An G,
    2. Wang H,
    3. Tang R,
    4. Yago T,
    5. McDaniel JM,
    6. McGee S,
    7. et al.
    P-selectin glycoprotein ligand-1 is highly expressed on Ly-6Chi monocytes and a major determinant for Ly-6Chi monocyte recruitment to sites of atherosclerosis in mice. Circulation 2008;117:3227–37.
    OpenUrlAbstract/FREE Full Text
  40. 40.↵
    1. Swirski FK,
    2. Libby P,
    3. Aikawa E,
    4. Alcaide P,
    5. Luscinskas FW,
    6. Weissleder R,
    7. et al.
    Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. J Clin Invest 2007;117:195–205.
    OpenUrlCrossRefPubMed
  41. 41.↵
    1. Ancuta P,
    2. Rao R,
    3. Moses A,
    4. Mehle A,
    5. Shaw SK,
    6. Luscinskas FW,
    7. et al.
    Fractalkine preferentially mediates arrest and migration of CD16+ monocytes. J Exp Med 2003;197:1701–7.
    OpenUrlAbstract/FREE Full Text
  42. 42.↵
    1. Grage-Griebenow E,
    2. Flad HD,
    3. Ernst M
    . Heterogeneity of human peripheral blood monocyte subsets. J Leukoc Biol 2001;69:11–20.
    OpenUrlAbstract/FREE Full Text
  43. 43.↵
    1. Gryglewski RJ,
    2. Palmer RM,
    3. Moncada S
    . Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature 1986;320:454–6.
    OpenUrlCrossRefPubMed
  44. 44.↵
    1. Meerschaert J,
    2. Furie MB
    . The adhesion molecules used by monocytes for migration across endothelium include CD11a/CD18, CD11b/CD18, and VLA-4 on monocytes and ICAM-1, VCAM-1, and other ligands on endothelium. J Immunol 1995;154:4099–112.
    OpenUrlAbstract
  45. 45.↵
    1. van Halm VP,
    2. van Denderen JC,
    3. Peters MJ,
    4. Twisk JW,
    5. van der Paardt M,
    6. van der Horst-Bruinsma IE,
    7. et al.
    Increased disease activity is associated with a deteriorated lipid profile in patients with ankylosing spondylitis. Ann Rheum Dis 2006;65:1473–7.
    OpenUrlAbstract/FREE Full Text
  46. 46.↵
    1. Papadakis JA,
    2. Sidiropoulos PI,
    3. Karvounaris SA,
    4. Vrentzos GE,
    5. Spanakis EK,
    6. Ganotakis ES,
    7. et al.
    High prevalence of metabolic syndrome and cardiovascular risk factors in men with ankylosing spondylitis on anti-TNFalpha treatment: correlation with disease activity. Clin Exp Rheumatol 2009;27:292–8.
    OpenUrlPubMed
  47. 47.↵
    1. Hwang SJ,
    2. Ballantyne CM,
    3. Sharrett AR,
    4. Smith LC,
    5. Davis CE,
    6. Gotto AM Jr.,
    7. et al.
    Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. Circulation 1997;96:4219–25.
    OpenUrlAbstract/FREE Full Text
  48. 48.↵
    1. Garlanda C,
    2. Bottazzi B,
    3. Moalli F,
    4. Deban L,
    5. Molla F,
    6. Latini R,
    7. et al.
    Pentraxins and atherosclerosis: the role of PTX3. Curr Pharm Des 2011;17:38–46.
    OpenUrlCrossRefPubMed
  49. 49.↵
    1. Jenny N,
    2. Arnold AM,
    3. Kuller LH,
    4. Tracy RP,
    5. Psaty BM
    . Association of pentraxin 3 with cardiovascular disease and all-cause death. The Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 2009;29:594–9.
    OpenUrlAbstract/FREE Full Text
  50. 50.↵
    1. Rothe G,
    2. Gabriel H,
    3. Kovacs E,
    4. Klucken J,
    5. Stöhr J,
    6. Kindermann W,
    7. et al.
    Peripheral blood mononuclear phagocyte subpopulations as cellular markers in hypercholesterolemia. Arterioscler Thromb Vasc Biol 1996;16:1437–47.
    OpenUrlAbstract/FREE Full Text
View Abstract
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 41, Issue 3
1 Mar 2014
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Blood Monocyte Heterogeneity and Markers of Endothelial Activation in Ankylosing Spondylitis
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Blood Monocyte Heterogeneity and Markers of Endothelial Activation in Ankylosing Spondylitis
Andrzej Surdacki, Joanna Sulicka, Mariusz Korkosz, Tomasz Mikołajczyk, Dorota Telesińska-Jasiówka, Ewa Klimek, Izabella Kierzkowska, Tomasz Guzik, Tomasz K. Grodzicki
The Journal of Rheumatology Mar 2014, 41 (3) 481-489; DOI: 10.3899/jrheum.130803

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Blood Monocyte Heterogeneity and Markers of Endothelial Activation in Ankylosing Spondylitis
Andrzej Surdacki, Joanna Sulicka, Mariusz Korkosz, Tomasz Mikołajczyk, Dorota Telesińska-Jasiówka, Ewa Klimek, Izabella Kierzkowska, Tomasz Guzik, Tomasz K. Grodzicki
The Journal of Rheumatology Mar 2014, 41 (3) 481-489; DOI: 10.3899/jrheum.130803
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters

Keywords

ANKYLOSING SPONDYLITIS
MONOCYTES
ENDOTHELIUM

Related Articles

Cited By...

More in this TOC Section

  • One-Third of European Patients with Axial Spondyloarthritis Reach Pain Remission With Routine Care Tumor Necrosis Factor Inhibitor Treatment
  • Oral Antiviral Treatment for COVID-19 in Patients With Systemic Autoimmune Rheumatic Diseases
  • The Positive Predictive Value of a Very High Serum IgG4 Concentration for the Diagnosis of IgG4-Related Disease
Show more Article

Similar Articles

Keywords

  • ANKYLOSING SPONDYLITIS
  • MONOCYTES
  • ENDOTHELIUM

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire